Dr Shamez Ladhani
Immunisation, Hepatitis and Blood Safety Department
Public Health England
61 Colindale Avenue
London NW9 5EQ
About the study
Approximately 85% of childhood meningitis in the conjugate vaccine era is due to enteroviruses and Human Parechoviruses (HPeV). Young infants are particularly susceptible to enterovirus and HPeV meningitis and often present with non-specific symptoms which are difficult to differentiate from serious bacterial infections. Real-time PCR is becoming increasingly available and it is anticipated that more cases will be diagnosed in the coming years.
There is, however, very limited data assessing the incidence, clinical features, sequale and outcome of infants with meningitis as a result of these viruses. This study will aim to improve our understanding of enterovirus and parechovirus meningitis, and also the outcomes.
Furthermore, there is no data linking the molecular subtypes of enteroviruses and HPeV currently circulating in the UK and Ireland with clinical severity, laboratory markers or outcomes. No specific antiviral treatments are licenced or in the immediate pipeline to treat these serious viruses. In part the lack of good clinical data defining the burden of disease is a barrier to the development of novel antiviral therapy.
You can download the protocol card, including references, below.
- S Kadambari, S Braccio, S Ribeiro, DJ Allen, R Pebody, D Brown, R Cunney, M Sharland, S Ladhani. 'Enterovirus and parechovirus meningitis in infants younger than 90 days old in the UK and Republic of Ireland: a British Paediatric Surveillance Unit study'. Archives of disease in childhood. Published Online First: 08 December 2018. doi:10.1136/archdischild-2018-31564.
- Any infant aged less than 90 days old with clinical symptoms of meningitis*, and
- Laboratory confirmation of enterovirus or parechovirus from any site**
July 2014 to July 2015 (13 months of surveillance) followed by a 12 month follow-up.
Paediatric Infectious Diseases Research Group, St George’s University of London.
This study has been approved by the NRES Committee London - Queen Square (Ref: 14/LO/0229). Public Health England has approval under Section 251 of the NHS Act 2006 to process confidential patient information for public health purposes. See The Health Service (Control of Patient Information) Regulations 2002.